Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308490 | 0.91 | GRM5 (0.43) | HDAC6GRM5KMT2AGAACYP1A2 | |
| SCHEMBL27141147 | 0.84 | NR1H2 (0.45) | HDAC6KMT2AGAASMN1; SMN2MEN1 | |
| SCHEMBL3309074 | 0.84 | CYP1A2 (0.40) | HDAC6KMT2AGAACYP1A2MEN1 | |
| SCHEMBL3313601 | 0.83 | L3MBTL1 (0.45) | KMT2AGAASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL25686948 | 0.83 | CYP1A2 (0.39) | HDAC6KMT2AGAACYP1A2ALDH1A1 | |
| SCHEMBL24812522 | 0.82 | RAB9A (0.37) | HDAC6KMT2AGAACYP1A2SMN1; SMN2 | |
| SCHEMBL2524047 | 0.81 | HDAC6 (0.70) | HDAC6GRM5KMT2AGAAL3MBTL1 | |
| SCHEMBL25412001 | 0.80 | GRM5 (0.46) | HDAC6GRM5 | |
| SCHEMBL16100677 | 0.79 | NPC1 (0.35) | HDAC6KMT2AGAACYP1A2SMN1; SMN2 | |
| SCHEMBL27137687 | 0.79 | KMT2A (0.36) | HDAC6KMT2AGAACYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577537-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| US-20250170126-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-05-29 | — | — | US | disclosed |
| WO-2024042007-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| US-20230416261-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | UNIV TEXAS (US) | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170126-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | HDAC6 1869/4885GRM5 1336/4885KMT2A 327/4885 |
| US-20230416261-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | PRMT1, PRMT7, PRMT5 | HDAC6 1265/4885GRM5 1725/4885KMT2A 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.